Novo Nordisk has started a new late-stage clinical study to evaluate lower maintenance doses of its oral obesity treatment Wegovy, according to information posted in a U.S. clinical trials database. The trial aims to determine the lowest dose of oral semaglutide, the active ingredient in Wegovy, that can still support weight loss in adults living with obesity or excess weight.
The study, known as OASIS-5, began on August 12 and is expected to continue until 2028. It will enroll 450 adult participants and compare lower doses of oral semaglutide with a placebo. The trial is being conducted across 62 sites in the United States and Europe.
Trial Designed to Evaluate Lower Maintenance Doses
The approved long-term maintenance dose of the Wegovy pill is currently 25 milligrams taken once daily. Novo Nordisk has not disclosed which lower dose strengths are being tested in the new study. However, the oral formulation of Wegovy is also approved in doses of 1.5 mg, 4 mg, and 9 mg.
In a statement provided to Reuters, Novo Nordisk said, “Having a broader range of maintenance doses could provide greater flexibility in treatment and optimising the patient experience.”
The company is seeking to determine whether lower doses of oral semaglutide help people lose more weight than a placebo over a 60-week period. Researchers will use percentage change in body weight as the primary measurement of the study.
Study Population and Key Measurements
Participants in the trial must have previously experienced difficulty losing weight and have a body mass index (BMI) of 30 or higher. Individuals with a BMI of at least 27 may also qualify if they have a weight-related health condition.
The study excludes people with diabetes, those who have recently undergone significant weight changes, and individuals currently receiving GLP-1-based treatments.
In addition to monitoring changes in body weight, researchers will assess how many participants achieve weight reductions of at least 5%, 10%, and 15% from their starting weight. The trial will also examine changes in waist circumference, blood pressure, blood sugar, cholesterol, triglycerides, and inflammation markers.
Safety will be another area of focus. Investigators will track side effects, serious adverse events, and treatment discontinuations for up to 67 weeks.
Interest in Lower Doses and Broader Health Outcomes
The study comes as some patients already use lower-than-approved doses of GLP-1 medicines, including Wegovy and Eli Lilly’s Zepbound. According to Novo Nordisk Chief Executive Officer Mike Doustdar, some individuals choose reduced doses on their own, often because of treatment costs or side effects.
Doustdar told Reuters that patients frequently seek benefits beyond weight reduction when using these medicines. He also said he expects the obesity treatment market to develop in a way that allows multiple products to coexist rather than being dominated by a single company.
Novo Nordisk’s new trial is intended to identify an effective lower oral semaglutide maintenance dose. The study is scheduled to run through April 2028, and the company has said the study will help it select the most effective lower oral semaglutide dose.
Wegovy maker Novo Nordisk has launched a new late-stage clinical trial designed to identify the lowest effective maintenance dose of its oral Wegovy weight-management treatment. The OASIS-5 study began on August 12, 2026, and is expected to run through 2028.
The Wegovy study will enroll 450 adults with obesity or overweight accompanied by weight-related health conditions. Researchers will compare two reduced doses of oral semaglutide with placebo to assess weight-loss effectiveness and other health outcomes.
Wegovy Study Focuses on Lower Doses
The new Wegovy trial reflects growing interest in determining whether patients can achieve meaningful weight-management benefits with smaller doses. Novo Nordisk has not yet disclosed the exact doses being tested in the study.
For Wegovy, identifying a lower effective dose could potentially give physicians and patients greater flexibility when managing treatment. Researchers will also evaluate whether lower dosing can help address tolerability concerns associated with GLP-1 therapies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
